Background
Immunoglobulin therapy has a wide range of indications, from the treatment of immunodeficiencies
to the control of autoimmune and inflammatory diseases. The number of potential
applications for immunoglobulin therapy continues to expand, and recent research
has highlighted several promising novel uses.
To demonstrate its continued commitment to innovative immunoglobulin research, CSL
Behring has created the Interlaken Leadership Awards.
Mission statement
The Interlaken Leadership Awards program was created to meet the following objectives:
- To identify new clinical applications for immunoglobulin therapy in the neurology field
- To further investigate the efficacy, mechanisms of action, and treatment optimization of polyvalent immunoglobulins
Program focus
The current focus of the Interlaken Leadership Awards program is to advance medical research and knowledge about the potential role
of immunoglobulin therapy in the treatment of neurological disorders.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We
research, develop, manufacture and market biotherapies that are used to treat serious
and rare conditions. Users of our therapies rely on them for their quality of life
and, in many cases, for life itself.
Our commitment to saving lives and improving the quality of life for people with
serious and rare conditions is evident in everything we do. Whether we are manufacturing
and marketing safe and effective products or researching and developing innovative
biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
For more than a century, CSL Behring has been providing safe, effective therapies to help improve the lives of people
affected by rare and serious medical conditions. In 1978 we produced the world’s first intact (unmodified) human IVIG
and then in 1999 was the first to manufacture chromatographically purified IVIG. Today, CSL
Behring continues to demonstrate its commitment to immunoglobulin research by sponsoring
the International Immunoglobulin Conference and the Interlaken Leadership Awards.